reports
SiriusPoint Welcomes AM Best Outlook Revision to ‘Positive’ from ‘Stab...
SiriusPoint Welcomes AM Best Outlook Revision to ‘Positive’ from ‘Stable’ HAMILTON, Bermuda, April 25, 2025 (GLOBE NEWSWIRE) -- AM Best has revised the outlook of the rated operating subsidiaries of SiriusPoint Ltd (“SiriusPoint” or “the Company”) (Bermuda) [NYSE: SPNT] to Positive from Stable, citing the Company’s “very strong balance sheet”. AM Best has affirmed the Financial Strength Rating of A- (Excellent) and the Long-Term Issuer Credit Ratings (Long-Term ICR) of “a-” (Excellent) of SiriusPoint’s rated operating subsidiaries. Additionally, the rating agency has affirmed the Long-Te...
SiriusPoint Announces Date for First Quarter 2025 Earnings Release
SiriusPoint Announces Date for First Quarter 2025 Earnings Release HAMILTON, Bermuda, April 22, 2025 (GLOBE NEWSWIRE) -- SiriusPoint Ltd. (NYSE: SPNT) (“SiriusPoint” or the “Company”) today announced that it is planning to release its first quarter 2025 financial results after the market close on Monday, May 5, 2025. The Company will also hold a webcast, which can also be accessed as a conference call, to discuss its financial results at 8:30 am (Eastern Time) on Tuesday May 6, 2025. The webcast of the live conference call can be accessed by logging onto the Investor Relations section of...
Lexicon Pharmaceuticals to Present at the 24th Annual Needham Virtual ...
Lexicon Pharmaceuticals to Present at the 24th Annual Needham Virtual Healthcare Conference THE WOODLANDS, Texas, April 02, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Company management will participate in a presentation at the 24th Annual Needham Virtual Healthcare Conference 2025 on Wednesday, April 9, at 8:00 a.m. ET. The live event and a replay of the presentation can be accessed via the Events page of the Company’s website at . About Lexicon Pharmaceuticals Lexicon is a biopharmaceutical company with a mission of pioneering medici...
Lexicon Pharmaceuticals Announces Exclusive License Agreement with Nov...
Lexicon Pharmaceuticals Announces Exclusive License Agreement with Novo Nordisk for LX9851 Lexicon eligible to receive up to $1 billion in upfront and development, regulatory and sales milestone payments, including $75 million in upfront and near-term milestone payments THE WOODLANDS, Texas, March 28, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that it has entered into an exclusive license agreement with Novo Nordisk A/S for LX9851, a first-in-class, oral non-incretin development candidate in obesity and associated metabolic disorders. Under the...
Lexicon Pharmaceuticals to Present at the Leerink Partners Global Heal...
Lexicon Pharmaceuticals to Present at the Leerink Partners Global Healthcare Conference 2025 THE WOODLANDS, Texas, March 07, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Company management will participate in a fireside chat at the Leerink Partners Global Healthcare Conference 2025 in Miami on Wednesday, March 12, at 10:00 a.m. ET. The live event and a replay of the presentation can be accessed via the Events page of the Company’s website at . About Lexicon Pharmaceuticals Lexicon is a biopharmaceutical company with a mission of pioneering m...
Lexicon Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Fina...
Lexicon Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates Topline Results for Phase 2b PROGRESS Study of Pilavapadin (LX9211) in Diabetic Peripheral Neuropathic Pain (DPNP); 10 mg dose to Advance into Phase 3 Development Leaner organization focused on Advancing Strong Pipeline Conference Call and Webcast at 5:00 pm ET THE WOODLANDS, Texas, March 06, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: LXRX), today reported financial results for the three months and year ended December 31, 2024, and provided an update on key corporate m...
Fitch Ratings Revises Outlook on SiriusPoint to Positive Based on Sign...
Fitch Ratings Revises Outlook on SiriusPoint to Positive Based on Significant Underwriting Performance Improvement HAMILTON, Bermuda, March 05, 2025 (GLOBE NEWSWIRE) -- Fitch Ratings (Fitch) has today announced that it has affirmed the ratings of SiriusPoint Ltd. (“SiriusPoint” or the “Company”), including its Long-Term Issuer Default Rating at ‘BBB’, its senior debt rating at ‘BBB-‘ and its Insurer Financial Strength (IFS) rating at ‘A-‘ (Strong) of SiriusPoint’s subsidiaries. It has also revised the Company’s Outlook to Positive from Stable. Fitch said: “The Positive Outlook reflects...
Lexicon Pharmaceuticals to Report Fourth Quarter and Full Year 2024 Fi...
Lexicon Pharmaceuticals to Report Fourth Quarter and Full Year 2024 Financial Results on March 6, 2025 THE WOODLANDS, Texas, March 04, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced the Company will release its fourth quarter and full year 2024 financial results on Thursday, March 6, 2025 after the markets close. Management will conduct a conference call and live webcast at 5:00 p.m. ET (4:00 p.m. CT) that day to discuss the financial results and to provide a business update. Participants can access the conference call live via webcast on the Events...
Lexicon Pharmaceuticals Announces Topline Results from Phase 2b PROGRE...
Lexicon Pharmaceuticals Announces Topline Results from Phase 2b PROGRESS Study Evaluating Pilavapadin (LX9211) in Adults with Diabetic Peripheral Neuropathic Pain Pilavapadin achieved meaningful pain reduction versus placebo and was well-tolerated in the 10 mg dose, meeting the Company’s objectives for the study Advancement of 10 mg dose into Phase 3 development in DPNP supported by both PROGRESS and RELIEF DPN-1 studies, which collectively enrolled approximately 600 pilavapadin-treated patients Conference call and webcast at 8:00 a.m. ET THE WOODLANDS, Texas, March 03, 2025...
Lexicon Pharmaceuticals to Announce Topline Results from Phase 2b PROG...
Lexicon Pharmaceuticals to Announce Topline Results from Phase 2b PROGRESS Study Evaluating Pilavapadin (LX9211) in Adults with Diabetic Peripheral Neuropathic Pain Conference call and webcast at 8:00 a.m. ET on Monday, March 3, 2025 THE WOODLANDS, Texas, March 02, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced the Company will hold a conference call and webcast on Monday, March 3, 2025 at 8:00 a.m. ET to share topline results from the Phase 2b PROGRESS (A Phase 2b, Dose-ranging, Randomized, Double-blind, PlacebO-controlled, Parallel-GRoup, MulticE...
SiriusPoint Announces Closing of CM Bermuda Transaction & Completion o...
SiriusPoint Announces Closing of CM Bermuda Transaction & Completion of Registered Secondary Offering of 4,106,631 Common Shares by Entities Associated with Daniel S. Loeb HAMILTON, Bermuda, Feb. 27, 2025 (GLOBE NEWSWIRE) -- SiriusPoint Ltd. (“SiriusPoint”) (NYSE: SPNT), a global specialty insurer and reinsurer, announced today the closing of its previously announced transaction to repurchase all SiriusPoint common shares and warrants held by CM Bermuda Limited (“CM Bermuda”) for an aggregate purchase price of $733 million. The Company also announced today the completion of the previously...
SiriusPoint Announces Pricing of Secondary Offering of 4,106,631 Commo...
SiriusPoint Announces Pricing of Secondary Offering of 4,106,631 Common Shares by Entities Associated with Daniel S. Loeb and Repurchase of 500,000 Shares by SiriusPoint HAMILTON, Bermuda, Feb. 25, 2025 (GLOBE NEWSWIRE) -- SiriusPoint Ltd. (“SiriusPoint” or the “Company”) (NYSE: SPNT) today announced the pricing of its previously announced registered secondary offering by entities associated with Daniel S. Loeb (colllectively, the “Loeb Entities”) of an aggregate of 4,106,631 common shares at a price to the public of $14.00 per share. The offering is expected to close on February 27, 2025...
SiriusPoint Announces Secondary Offering of 4,106,631 Common Shares by...
SiriusPoint Announces Secondary Offering of 4,106,631 Common Shares by Entities Associated with Daniel S. Loeb and Potential Repurchase of up to 2,000,000 Common Shares by SiriusPoint HAMILTON, Bermuda, Feb. 25, 2025 (GLOBE NEWSWIRE) -- SiriusPoint Ltd. (“SiriusPoint” or the “Company”) (NYSE: SPNT) today announced that entities associated with Daniel S. Loeb (collectively, the “Loeb Entities”) are offering an aggregate of 4,106,631 common shares through a registered secondary offering. SiriusPoint has indicated its intent to repurchase an aggregate of up to 2,000,000 of the common share...
SiriusPoint reports ninth consecutive quarter of underwriting profits ...
SiriusPoint reports ninth consecutive quarter of underwriting profits with FY Core combined ratio of 91.0% HAMILTON, Bermuda, Feb. 18, 2025 (GLOBE NEWSWIRE) -- SiriusPoint Ltd. (“SiriusPoint” or the “Company”) (NYSE:SPNT) today announced results for its fourth quarter ended December 31, 2024 Combined ratio of 90.2% in the fourth quarter for Core business, representing a 3.2 point improvement versus prior year, resulting in a full year 2024 Core combined ratio of 91.0% and Core underwriting income of $200 millionGrowth in the quarter of 21% on gross premiums written for continuing lines b...
Published Data in The Lancet Diabetes & Endocrinology Highlights Uniqu...
Published Data in The Lancet Diabetes & Endocrinology Highlights Unique Efficacy Benefits of Sotagliflozin to Reduce Major Adverse Cardiovascular Events (MACE) Data reinforce unique clinical advantages of sotagliflozin Published study is aligned with research presented in December 2024 at the American Society of Hematology showing clinical benefits of sotagliflozin compared to empagliflozin THE WOODLANDS, Texas, Feb. 18, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced The Lancet Diabetes & Endocrinology has published a research paper analyzing t...
SiriusPoint Announces Date for Fourth Quarter and Full Year 2024 Earni...
SiriusPoint Announces Date for Fourth Quarter and Full Year 2024 Earnings Release HAMILTON, Bermuda, Feb. 05, 2025 (GLOBE NEWSWIRE) -- SiriusPoint Ltd. (NYSE: SPNT) (“SiriusPoint” or the “Company”) today announced that it is planning to release its fourth quarter and full year 2024 financial results after the market close on Tuesday, February 18, 2025. The Company will also hold a webcast, which can also be accessed as a conference call, to discuss its financial results at 8:30 am (Eastern Time) on Wednesday, February 19, 2025. The webcast of the live conference call can be accessed by l...
SiriusPoint Announces Dividend on Series B Preference Shares
SiriusPoint Announces Dividend on Series B Preference Shares HAMILTON, Bermuda, Jan. 29, 2025 (GLOBE NEWSWIRE) -- SiriusPoint Ltd. (“SiriusPoint” or the “Company”) (NYSE: SPNT), a global specialty insurer and reinsurer, has today announced that the Audit Committee of the Board of Directors of SiriusPoint Ltd. has approved a quarterly cash dividend of $0.50 per share on its 8.00% Resettable Fixed Rate Preference Shares, Series B, $0.10 par value, $25.00 liquidation preference per share payable on or prior to February 28, 2025 to Series B shareholders of record as of February 13, 2025. Abo...
Lexicon Announces Virtual Webcast on LX9211 for Diabetic Peripheral Ne...
Lexicon Announces Virtual Webcast on LX9211 for Diabetic Peripheral Neuropathic Pain Event will feature insights on LX9211, Lexicon’s novel, investigational, non-opioid treatment, as well as expert panel and Q&A session on DPNP THE WOODLANDS, Texas, Jan. 21, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that the company will host a virtual webcast: “LX9211 - Changing the Paradigm for Treatment of Neuropathic Pain.” The event will be held from 9:00 a.m. to 11:00 a.m. ET on January 28, 2025. In advance of topline data from the Phase 2b PROGRESS tri...
Lexicon Appoints Scott Coiante as Chief Financial Officer
Lexicon Appoints Scott Coiante as Chief Financial Officer THE WOODLANDS, Texas, Jan. 02, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced the appointment of Scott Coiante as senior vice president and chief financial officer, effective today, January 2, 2025. Mr. Coiante is a senior finance executive with more than 35 years of experience in the life science and pharmaceutical industries. He joins Lexicon from Agile Therapeutics, where he served as the senior vice president, chief financial officer and treasurer of Agile Therapeutics Inc. from A...
SiriusPoint Announces Full Repurchase of CM Bermuda Shares
SiriusPoint Announces Full Repurchase of CM Bermuda Shares HAMILTON, Bermuda, Dec. 30, 2024 (GLOBE NEWSWIRE) -- SiriusPoint Ltd. (“SiriusPoint”) (NYSE: SPNT), a global specialty insurer and reinsurer, announced today it has entered into an agreement to repurchase all SiriusPoint common shares and warrants held by CM Bermuda Limited (“CM Bermuda”) for an aggregate purchase price of $733 million. Following the closing of the repurchase transaction, CM Bermuda will have no remaining ownership interest in SiriusPoint and will cease to have any representation on, or observer rights with respe...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.